[Illustrations de Histoire de la mission des Pères Capucins en l'Isle de Maragnan et terres circonvoisines...] / L. Gaultier [grav.] ; Le Père Claude d'Abbeville, aut. du texte

Comprend : [Frontispice : Pape, moine, personnification de l'Eglise. Armoiries. XVIè siècle.] [cote : microfilm m 10858/R 15836] ; [pl. en reg. p.90 : élévation d'une croix pour la bénédiction de l'Ile de Maragnan. XVIIè siècle.] [cote : microfilm m 10858/R 15836] ; [pl. en reg. p.348 : indigène de l'Ile de Maragnan, nommé François Carypyra, de la tribu des Tabaiares. XVIIè siècle.] François Carypyra. [cote : microfilm m 10858/R 15836] ; [pl. en reg. p.356 : indigène de l'Ile de Maragnan, nommé Jacques Patova. XVIIè siècle.] Jacques Patova. [cote : microfilm m 10858/R 15836] ; [pl. en reg. p.359 : indigène de l'Ile de Maragnan, nommé Antoine Manen, natif de Renary, originaire de Para de l'Ouest. XVIIè siècle.] Anthoine Manen. [cote : microfilm m 10858/R 15836] ; [pl. en reg. p.362 : indigène de l'Ile de Maragnan, nommé Itapoucou Topinamba et baptisé Louis-Marie. XVIIè siècle.] Louis Marie. [cote : microfilm m 10858/R 15836] ; [pl. en reg. p.364 : indigène de l'Ile de Maragnan, nommé Ouäroyio Topinamba et baptisé Louis-Henry. XVIIè siècle.] Louis Henri. [cote : microfilm m 10858/R 15836] ; [pl. en reg. p.365 : indigène de l'Ile de Maragnan, nommé Iapouäy et baptisé Louis de Saint-Jean. XVIIè siècle.] Louis de St. Iehan. [cote : microfilm m 10858/R 15836]

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

PURPOSE: To centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by immunohistochemistry and investigate their predictive value for benefit of chemo-endocrine compared with endocrine adjuvant therapy alone in two randomized clinical trials for node-negative breast cancer. PATIENTS AND METHODS: International Breast Cancer Study Group Trial VIII compared cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for 6 cycles followed by endocrine therapy with goserelin with either modality alone in pre- and perimenopausal patients. Trial IX compared three cycles of CMF followed by tamoxifen for 5 years versus tamoxifen alone in postmenopausal patients. Central Pathology Office reviewed 883 (83%) of 1,063 patients on Trial VIII and 1,365 (82%) of 1,669 on Trial IX and determined ER and PgR by immunohistochemistry. Disease-free survival (DFS) was compared across the spectrum of expression of each receptor using the Subpopulation Treatment Effect Pattern Plot methodology. RESULTS: Both receptors displayed a bimodal distribution, with substantial proportions showing no staining (receptor absent) and most of the remainder showing a high percentage of stained cells. Chemo-endocrine therapy yielded DFS superior to endocrine therapy alone for patients with receptor-absent tumors, and in some cases also for those with low levels of receptor expression. Among patients with ER-expressing tumors, additional prediction of benefit was suggested in absent or low PgR in Trial VIII but not in Trial IX. CONCLUSION: Low levels of ER and PgR are predictive of the benefit of adding chemotherapy to endocrine therapy. Low PgR may add further prediction among pre- and perimenopausal but not postmenopausal patients whose tumors express ER.

Record of Decision Council Bluffs Interstate System (I-29, I-80 and I-480) Improvements Project TIER 1 Environmental Impact Statement Council Bluffs, Iowa to Omaha, Nebraska FHWA-IA- EIS-04-01F Project Number: IM-029-3(62)54—13-78 Submitted Pursuant to 42 USC 4332(2)(c) and 49 USC 303, October 2008

The Federal Highway Administration (FHWA) approves the selection of the Reconstruction of All or Part of the Interstate (Construction Alternative) as the Preferred Alternative to provide improvements to the interstate system in the Omaha/Council Bluffs metropolitan area, extending across the Missouri River on Interstate 80 to east of the Interstate 480 interchange in Omaha, Nebraska. The study considered long-term, broad-based transportation improvements along Interstate I-29 (I-29), I-80, and I-480, including approximately 18 mainline miles of interstate and 14 interchanges (3 system, 11 service), that would add capacity and correct functional issues along the mainline and interchanges and upgrade the I-80 Missouri River Crossing. FHWA also approves the decisions to provide full access between West Broadway and I-29, design the I-80/I-29 overlap section as a dual-divided freeway, and locating the new I-80 Missouri River Bridge north of the existing bridge. Improvements to the interstate system, once implemented, would bring the segments of I-80 and I-29 (see Figure 1) up to current engineering standards and accommodate future traffic needs. This Record of Decision (ROD) concludes Tier 1 of the Council Bluffs Interstate System (CBIS) Improvements Project. Tier 1 included an examination of the area’s transportation needs, a study of alternatives to satisfy them, and broad consideration of potential environmental and social impacts. The Tier 1 evaluation consisted of a sufficient level of engineering and environmental detail to assist decision makers in selecting a preferred transportation strategy. During Tier 1 a Draft EIS (FHWA-IA- EIS-04-01D) was developed which was approved by FHWA, Iowa DOT, and Nebraska Department of Roads (NDOR) in November 2004 with comments accepted through March 15, 2005. The Draft EIS summarized the alternatives that were considered to address the transportation needs around Council Bluffs; identified reconstruction of all or part of the interstate, the “Construction Alternative,” as the Preferred Alternative; identified three system-level decisions that needed to be made at the Tier 1 level; and invited comment on the issues. The Final EIS (FHWA-IA- EIS-04-01F) further documented the Construction Alternative as the Preferred Alternative and identified the recommended decisions for the three system level decisions that needed to be made in Tier 1. This ROD defines the Selected Alternative determined in the Tier 1 studies.